This preliminary result suggests that high baseline level of serum proBDNF could be used to predict poor improvement of motor function in the affected upper limbs, or alternatively, used as a biomarker of the response to rehabilitation in poststroke patients with hemiparesis. The gene discussed is BDNF; the disease is Hemiparesis.